Mednow Launches New Virtual Diabetes Management Program in Partnership With Dexcom

Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Feb 02, 2023 07:00 am

Mednow Inc. (“Mednow” or the “Company”) (TSXV: MNOW) (OTCQX: MDNWF) announced today the launch of its enhanced Virtual Diabetes Management program, an end-to-end digital diabetes management solution, to enable convenient on-demand access to Dexcom G6 (NASDAQ: DXCM) real-time continuous glucose monitoring (rtCGM) supplies and personalized diabetes care services.

The new integrated Virtual Diabetes Management program combines Mednow virtual pharmacy services with Dexcom rtCGM technology, to provide individuals with a comprehensive diabetes management solution. Services include access to a team of certified diabetes educators (CDEs) and clinical pharmacists for ongoing health coaching, personalization of treatment, and convenient home delivery of all diabetes-related medications and supplies.

The Mednow clinical team will utilize the Dexcom Clarity data platform, to integrate individual glucose patterns and trends into personalized coaching and care. For individuals without access to a physician, Mednow’s Virtual Care service can connect them with a licensed Canadian clinician who can offer medical advice, diagnose, and prescribe, online or on the phone. The Virtual Diabetes Management program will initially be available in Ontario and British Columbia starting in early February. To access the program, go to

“Mednow is thrilled to partner with Dexcom Canada and bring cutting edge health solutions to patients across Canada living with diabetes,” said Ali Reyhany, CEO of Mednow. “Our virtual pharmacy services, combined with Dexcom's rtCGM technology, will provide patients with a more convenient and accessible solution for managing their condition. This program and partnership strongly align with our vision of utilizing innovative technologies to support patients in managing their care at home. Further, this leverages our investments in diabetes, including access to multilingual Certified Diabetes Educators, virtual pharmacist access, nutritional support, and preferred pricing for other non-prescription diabetic supplies.”

The Dexcom G6 rtCGM system uses a small, wearable sensor and transmitter to continuously monitor and send glucose levels wirelessly to a smart device* or receiver, giving patients real-time glucose data without the need to scan or routinely prick their finger†. The system has customizable alerts, including a predictive low glucose alert which can help patients take action to avoid potentially dangerous low blood sugar events (<3.1 mmol/L), and a function that allows patients to share their glucose data with up to 10 followers. The use of Dexcom rtCGM is proven to improve glycemic controli,ii and can reduce the risk of costly long-term diabetes-related complicationsiii. Dexcom G6 also offers industry-leading connectivity through integrations with leading insulin delivery systems and digital health apps.

“Our goal at Dexcom is to help those living with diabetes manage their condition proactively and efficiently, throughout every step of their journey,” said André Côté, General Manager of Dexcom Canada. “This includes how they access the system. We’ve learned that three-quarters of Dexcom users prefer to access their Dexcom rtCGM supplies from a pharmacy. In response, we’ve partnered with Mednow to provide users with a more convenient and coordinated experience, by making Dexcom G6 sensors and transmitters available through the pharmacy combined with enhanced virtual diabetes management support services.”

About Mednow:

Mednow is a healthcare technology company offering virtual access with a high-standard of care. Designed with accessibility and quality of care in mind, Mednow provides virtual pharmacy and telemedicine services as well as doctor home visits through an interdisciplinary approach to healthcare that is focused on the patient experience. Mednow’s services include free at-home delivery of medications, doctor consultations, a user-friendly interface for easy upload, transfer, and refill of prescriptions, access to healthcare professionals through an intuitive chat experience and the specialized PillSmart™ system that packages prescriptions in easy-to-use daily dose packs, each labeled with the date and time of the next dose. To learn more, follow Mednow on Facebook, Twitter, LinkedIn, and Instagram, or visit our website at

* For a list of compatible devices, please visit

If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.


  1. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017;317(4):371-8.
  2. Welsh JB, Gao P, Derdzinski M, et al. Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems. Diabetes Technol Ther 2019;21(3):128-32.
  3. Roze S, Isitt J, Smith-Palmer J, Lynch P. Evaluation of the Long-Term Cost-Effectiveness of the Dexcom G6 Continuous Glucose Monitor Versus Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in Canada. Poster presentation presented at: 2020 Canadian Association for Population Therapeutics; October 27, 2020.


Lorraine Cardenas
[email protected]

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).